nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP1A2—Sorafenib—thyroid cancer	0.108	0.277	CbGbCtD
Alosetron—CYP2C9—Sorafenib—thyroid cancer	0.0977	0.249	CbGbCtD
Alosetron—CYP3A4—Vandetanib—thyroid cancer	0.0943	0.241	CbGbCtD
Alosetron—CYP3A4—Sorafenib—thyroid cancer	0.0568	0.145	CbGbCtD
Alosetron—CYP3A4—Doxorubicin—thyroid cancer	0.0345	0.088	CbGbCtD
Alosetron—Viral diarrhoea—Vandetanib—thyroid cancer	0.0322	0.0529	CcSEcCtD
Alosetron—Diverticulitis—Vandetanib—thyroid cancer	0.0257	0.0423	CcSEcCtD
Alosetron—Balance disorder—Vandetanib—thyroid cancer	0.0154	0.0252	CcSEcCtD
Alosetron—Cholecystitis—Vandetanib—thyroid cancer	0.0146	0.024	CcSEcCtD
Alosetron—Folliculitis—Vandetanib—thyroid cancer	0.0134	0.022	CcSEcCtD
Alosetron—Nail disorder—Vandetanib—thyroid cancer	0.0129	0.0213	CcSEcCtD
Alosetron—Ileus—Vandetanib—thyroid cancer	0.0119	0.0195	CcSEcCtD
Alosetron—Laryngitis—Vandetanib—thyroid cancer	0.0116	0.0191	CcSEcCtD
Alosetron—Tachyarrhythmia—Epirubicin—thyroid cancer	0.0115	0.0188	CcSEcCtD
Alosetron—Fungal infection—Vandetanib—thyroid cancer	0.0109	0.0179	CcSEcCtD
Alosetron—Tachyarrhythmia—Doxorubicin—thyroid cancer	0.0106	0.0174	CcSEcCtD
Alosetron—Acne—Vandetanib—thyroid cancer	0.00997	0.0164	CcSEcCtD
Alosetron—Cholecystitis—Sorafenib—thyroid cancer	0.00986	0.0162	CcSEcCtD
Alosetron—Folliculitis—Sorafenib—thyroid cancer	0.00901	0.0148	CcSEcCtD
Alosetron—Haematoma—Sorafenib—thyroid cancer	0.00901	0.0148	CcSEcCtD
Alosetron—Proctitis—Epirubicin—thyroid cancer	0.00857	0.0141	CcSEcCtD
Alosetron—Cystitis noninfective—Vandetanib—thyroid cancer	0.0082	0.0135	CcSEcCtD
Alosetron—Cystitis—Vandetanib—thyroid cancer	0.0081	0.0133	CcSEcCtD
Alosetron—Colitis—Vandetanib—thyroid cancer	0.00806	0.0132	CcSEcCtD
Alosetron—Proctitis—Doxorubicin—thyroid cancer	0.00793	0.013	CcSEcCtD
Alosetron—Bladder pain—Vandetanib—thyroid cancer	0.00759	0.0125	CcSEcCtD
Alosetron—Gastroenteritis—Vandetanib—thyroid cancer	0.00687	0.0113	CcSEcCtD
Alosetron—Hypoglycaemia—Vandetanib—thyroid cancer	0.00624	0.0103	CcSEcCtD
Alosetron—Drug interaction—Sorafenib—thyroid cancer	0.0061	0.01	CcSEcCtD
Alosetron—Blood pressure increased—Sorafenib—thyroid cancer	0.00566	0.00931	CcSEcCtD
Alosetron—Nasopharyngitis—Vandetanib—thyroid cancer	0.00545	0.00896	CcSEcCtD
Alosetron—Gastritis—Vandetanib—thyroid cancer	0.00539	0.00886	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00537	0.00883	CcSEcCtD
Alosetron—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00489	0.00805	CcSEcCtD
Alosetron—Pollakiuria—Vandetanib—thyroid cancer	0.00486	0.008	CcSEcCtD
Alosetron—Hyperglycaemia—Vandetanib—thyroid cancer	0.00475	0.00781	CcSEcCtD
Alosetron—Depression—Vandetanib—thyroid cancer	0.00468	0.0077	CcSEcCtD
Alosetron—Eczema—Sorafenib—thyroid cancer	0.00457	0.00752	CcSEcCtD
Alosetron—Urinary tract infection—Vandetanib—thyroid cancer	0.00456	0.0075	CcSEcCtD
Alosetron—Sinusitis—Vandetanib—thyroid cancer	0.0044	0.00724	CcSEcCtD
Alosetron—Haemoglobin—Vandetanib—thyroid cancer	0.00424	0.00696	CcSEcCtD
Alosetron—Haemorrhage—Vandetanib—thyroid cancer	0.00421	0.00693	CcSEcCtD
Alosetron—Arrhythmia—Vandetanib—thyroid cancer	0.00376	0.00619	CcSEcCtD
Alosetron—Abdominal pain upper—Sorafenib—thyroid cancer	0.00375	0.00617	CcSEcCtD
Alosetron—Alopecia—Vandetanib—thyroid cancer	0.00372	0.00612	CcSEcCtD
Alosetron—Nasopharyngitis—Sorafenib—thyroid cancer	0.00367	0.00604	CcSEcCtD
Alosetron—Gastritis—Sorafenib—thyroid cancer	0.00364	0.00598	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00362	0.00596	CcSEcCtD
Alosetron—Muscle spasms—Vandetanib—thyroid cancer	0.00353	0.0058	CcSEcCtD
Alosetron—Tremor—Vandetanib—thyroid cancer	0.00344	0.00565	CcSEcCtD
Alosetron—Abdominal discomfort—Sorafenib—thyroid cancer	0.0034	0.0056	CcSEcCtD
Alosetron—Folliculitis—Epirubicin—thyroid cancer	0.00333	0.00547	CcSEcCtD
Alosetron—Nail disorder—Epirubicin—thyroid cancer	0.00323	0.0053	CcSEcCtD
Alosetron—Cough—Vandetanib—thyroid cancer	0.0032	0.00526	CcSEcCtD
Alosetron—Hypertension—Vandetanib—thyroid cancer	0.00317	0.00521	CcSEcCtD
Alosetron—Anxiety—Vandetanib—thyroid cancer	0.00311	0.00512	CcSEcCtD
Alosetron—Jaundice—Sorafenib—thyroid cancer	0.00309	0.00508	CcSEcCtD
Alosetron—Folliculitis—Doxorubicin—thyroid cancer	0.00308	0.00506	CcSEcCtD
Alosetron—Dry mouth—Vandetanib—thyroid cancer	0.00305	0.00502	CcSEcCtD
Alosetron—Burning sensation—Epirubicin—thyroid cancer	0.00301	0.00495	CcSEcCtD
Alosetron—Nail disorder—Doxorubicin—thyroid cancer	0.00298	0.00491	CcSEcCtD
Alosetron—Infection—Vandetanib—thyroid cancer	0.00297	0.00489	CcSEcCtD
Alosetron—Ileus—Epirubicin—thyroid cancer	0.00296	0.00486	CcSEcCtD
Alosetron—Skin disorder—Vandetanib—thyroid cancer	0.00291	0.00478	CcSEcCtD
Alosetron—Laryngitis—Epirubicin—thyroid cancer	0.0029	0.00477	CcSEcCtD
Alosetron—Haemoglobin—Sorafenib—thyroid cancer	0.00286	0.0047	CcSEcCtD
Alosetron—Haemorrhage—Sorafenib—thyroid cancer	0.00284	0.00467	CcSEcCtD
Alosetron—Dermatitis atopic—Epirubicin—thyroid cancer	0.00283	0.00465	CcSEcCtD
Alosetron—Burning sensation—Doxorubicin—thyroid cancer	0.00279	0.00458	CcSEcCtD
Alosetron—Ileus—Doxorubicin—thyroid cancer	0.00274	0.0045	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00273	0.00448	CcSEcCtD
Alosetron—Fungal infection—Epirubicin—thyroid cancer	0.00271	0.00445	CcSEcCtD
Alosetron—Laryngitis—Doxorubicin—thyroid cancer	0.00269	0.00442	CcSEcCtD
Alosetron—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00262	0.0043	CcSEcCtD
Alosetron—Fatigue—Vandetanib—thyroid cancer	0.00258	0.00424	CcSEcCtD
Alosetron—Pain—Vandetanib—thyroid cancer	0.00256	0.00421	CcSEcCtD
Alosetron—Constipation—Vandetanib—thyroid cancer	0.00256	0.00421	CcSEcCtD
Alosetron—Arrhythmia—Sorafenib—thyroid cancer	0.00254	0.00418	CcSEcCtD
Alosetron—Alopecia—Sorafenib—thyroid cancer	0.00251	0.00413	CcSEcCtD
Alosetron—Fungal infection—Doxorubicin—thyroid cancer	0.00251	0.00412	CcSEcCtD
Alosetron—Muscle spasms—Sorafenib—thyroid cancer	0.00238	0.00391	CcSEcCtD
Alosetron—Ulcer—Epirubicin—thyroid cancer	0.00221	0.00364	CcSEcCtD
Alosetron—Bone pain—Epirubicin—thyroid cancer	0.00218	0.00359	CcSEcCtD
Alosetron—Cough—Sorafenib—thyroid cancer	0.00216	0.00355	CcSEcCtD
Alosetron—Asthenia—Vandetanib—thyroid cancer	0.00215	0.00353	CcSEcCtD
Alosetron—Hypertension—Sorafenib—thyroid cancer	0.00214	0.00351	CcSEcCtD
Alosetron—Myalgia—Sorafenib—thyroid cancer	0.00211	0.00346	CcSEcCtD
Alosetron—Abnormal dreams—Epirubicin—thyroid cancer	0.00207	0.0034	CcSEcCtD
Alosetron—Dry mouth—Sorafenib—thyroid cancer	0.00206	0.00339	CcSEcCtD
Alosetron—Ulcer—Doxorubicin—thyroid cancer	0.00205	0.00336	CcSEcCtD
Alosetron—Cystitis noninfective—Epirubicin—thyroid cancer	0.00204	0.00336	CcSEcCtD
Alosetron—Bone pain—Doxorubicin—thyroid cancer	0.00202	0.00332	CcSEcCtD
Alosetron—Cystitis—Epirubicin—thyroid cancer	0.00202	0.00332	CcSEcCtD
Alosetron—Colitis—Epirubicin—thyroid cancer	0.00201	0.0033	CcSEcCtD
Alosetron—Infection—Sorafenib—thyroid cancer	0.00201	0.0033	CcSEcCtD
Alosetron—Skin disorder—Sorafenib—thyroid cancer	0.00196	0.00323	CcSEcCtD
Alosetron—Abnormal dreams—Doxorubicin—thyroid cancer	0.00191	0.00315	CcSEcCtD
Alosetron—Vomiting—Vandetanib—thyroid cancer	0.0019	0.00313	CcSEcCtD
Alosetron—Bladder pain—Epirubicin—thyroid cancer	0.00189	0.00311	CcSEcCtD
Alosetron—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00189	0.00311	CcSEcCtD
Alosetron—Rash—Vandetanib—thyroid cancer	0.00189	0.0031	CcSEcCtD
Alosetron—Dermatitis—Vandetanib—thyroid cancer	0.00189	0.0031	CcSEcCtD
Alosetron—Headache—Vandetanib—thyroid cancer	0.00188	0.00308	CcSEcCtD
Alosetron—Cystitis—Doxorubicin—thyroid cancer	0.00187	0.00307	CcSEcCtD
Alosetron—Colitis—Doxorubicin—thyroid cancer	0.00186	0.00306	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00184	0.00303	CcSEcCtD
Alosetron—Nausea—Vandetanib—thyroid cancer	0.00178	0.00292	CcSEcCtD
Alosetron—Bladder pain—Doxorubicin—thyroid cancer	0.00175	0.00288	CcSEcCtD
Alosetron—Fatigue—Sorafenib—thyroid cancer	0.00174	0.00286	CcSEcCtD
Alosetron—Pain—Sorafenib—thyroid cancer	0.00173	0.00284	CcSEcCtD
Alosetron—Constipation—Sorafenib—thyroid cancer	0.00173	0.00284	CcSEcCtD
Alosetron—Eczema—Epirubicin—thyroid cancer	0.00169	0.00278	CcSEcCtD
Alosetron—Urticaria—Sorafenib—thyroid cancer	0.0016	0.00264	CcSEcCtD
Alosetron—Eczema—Doxorubicin—thyroid cancer	0.00156	0.00257	CcSEcCtD
Alosetron—Hypoglycaemia—Epirubicin—thyroid cancer	0.00156	0.00256	CcSEcCtD
Alosetron—Hypersensitivity—Sorafenib—thyroid cancer	0.00149	0.00245	CcSEcCtD
Alosetron—Asthenia—Sorafenib—thyroid cancer	0.00145	0.00238	CcSEcCtD
Alosetron—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00144	0.00237	CcSEcCtD
Alosetron—Abdominal pain upper—Epirubicin—thyroid cancer	0.00139	0.00228	CcSEcCtD
Alosetron—Nasopharyngitis—Epirubicin—thyroid cancer	0.00136	0.00223	CcSEcCtD
Alosetron—Gastritis—Epirubicin—thyroid cancer	0.00134	0.00221	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00134	0.0022	CcSEcCtD
Alosetron—Abdominal distension—Epirubicin—thyroid cancer	0.00132	0.00217	CcSEcCtD
Alosetron—Vomiting—Sorafenib—thyroid cancer	0.00128	0.00211	CcSEcCtD
Alosetron—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00128	0.00211	CcSEcCtD
Alosetron—Rash—Sorafenib—thyroid cancer	0.00127	0.00209	CcSEcCtD
Alosetron—Dermatitis—Sorafenib—thyroid cancer	0.00127	0.00209	CcSEcCtD
Alosetron—Headache—Sorafenib—thyroid cancer	0.00127	0.00208	CcSEcCtD
Alosetron—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00126	0.00207	CcSEcCtD
Alosetron—Gastritis—Doxorubicin—thyroid cancer	0.00124	0.00204	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00124	0.00204	CcSEcCtD
Alosetron—Abdominal distension—Doxorubicin—thyroid cancer	0.00122	0.00201	CcSEcCtD
Alosetron—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00122	0.00201	CcSEcCtD
Alosetron—Pollakiuria—Epirubicin—thyroid cancer	0.00121	0.00199	CcSEcCtD
Alosetron—Nausea—Sorafenib—thyroid cancer	0.0012	0.00197	CcSEcCtD
Alosetron—Hyperglycaemia—Epirubicin—thyroid cancer	0.00118	0.00195	CcSEcCtD
Alosetron—Jaundice—Epirubicin—thyroid cancer	0.00114	0.00188	CcSEcCtD
Alosetron—Urinary tract infection—Epirubicin—thyroid cancer	0.00114	0.00187	CcSEcCtD
Alosetron—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00113	0.00186	CcSEcCtD
Alosetron—Sweating—Epirubicin—thyroid cancer	0.00112	0.00184	CcSEcCtD
Alosetron—Pollakiuria—Doxorubicin—thyroid cancer	0.00112	0.00184	CcSEcCtD
Alosetron—Sinusitis—Epirubicin—thyroid cancer	0.0011	0.00181	CcSEcCtD
Alosetron—Hyperglycaemia—Doxorubicin—thyroid cancer	0.0011	0.0018	CcSEcCtD
Alosetron—Haemoglobin—Epirubicin—thyroid cancer	0.00106	0.00174	CcSEcCtD
Alosetron—Jaundice—Doxorubicin—thyroid cancer	0.00106	0.00174	CcSEcCtD
Alosetron—Urinary tract infection—Doxorubicin—thyroid cancer	0.00105	0.00173	CcSEcCtD
Alosetron—Hepatitis—Epirubicin—thyroid cancer	0.00105	0.00173	CcSEcCtD
Alosetron—Haemorrhage—Epirubicin—thyroid cancer	0.00105	0.00173	CcSEcCtD
Alosetron—Hypoaesthesia—Epirubicin—thyroid cancer	0.00105	0.00172	CcSEcCtD
Alosetron—Sweating—Doxorubicin—thyroid cancer	0.00104	0.00171	CcSEcCtD
Alosetron—Sinusitis—Doxorubicin—thyroid cancer	0.00102	0.00167	CcSEcCtD
Alosetron—Haemoglobin—Doxorubicin—thyroid cancer	0.000977	0.00161	CcSEcCtD
Alosetron—Haemorrhage—Doxorubicin—thyroid cancer	0.000972	0.0016	CcSEcCtD
Alosetron—Hepatitis—Doxorubicin—thyroid cancer	0.000972	0.0016	CcSEcCtD
Alosetron—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000967	0.00159	CcSEcCtD
Alosetron—Arrhythmia—Epirubicin—thyroid cancer	0.000939	0.00154	CcSEcCtD
Alosetron—Alopecia—Epirubicin—thyroid cancer	0.000928	0.00153	CcSEcCtD
Alosetron—Flatulence—Epirubicin—thyroid cancer	0.000901	0.00148	CcSEcCtD
Alosetron—Muscle spasms—Epirubicin—thyroid cancer	0.000879	0.00145	CcSEcCtD
Alosetron—Arrhythmia—Doxorubicin—thyroid cancer	0.000868	0.00143	CcSEcCtD
Alosetron—Alopecia—Doxorubicin—thyroid cancer	0.000859	0.00141	CcSEcCtD
Alosetron—Ill-defined disorder—Epirubicin—thyroid cancer	0.000849	0.0014	CcSEcCtD
Alosetron—Flatulence—Doxorubicin—thyroid cancer	0.000834	0.00137	CcSEcCtD
Alosetron—Malaise—Epirubicin—thyroid cancer	0.000825	0.00136	CcSEcCtD
Alosetron—Muscle spasms—Doxorubicin—thyroid cancer	0.000814	0.00134	CcSEcCtD
Alosetron—Cough—Epirubicin—thyroid cancer	0.000798	0.00131	CcSEcCtD
Alosetron—Hypertension—Epirubicin—thyroid cancer	0.00079	0.0013	CcSEcCtD
Alosetron—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000785	0.00129	CcSEcCtD
Alosetron—Myalgia—Epirubicin—thyroid cancer	0.000779	0.00128	CcSEcCtD
Alosetron—Anxiety—Epirubicin—thyroid cancer	0.000776	0.00128	CcSEcCtD
Alosetron—Discomfort—Epirubicin—thyroid cancer	0.000769	0.00126	CcSEcCtD
Alosetron—Malaise—Doxorubicin—thyroid cancer	0.000763	0.00125	CcSEcCtD
Alosetron—Dry mouth—Epirubicin—thyroid cancer	0.000762	0.00125	CcSEcCtD
Alosetron—Confusional state—Epirubicin—thyroid cancer	0.000753	0.00124	CcSEcCtD
Alosetron—Infection—Epirubicin—thyroid cancer	0.000742	0.00122	CcSEcCtD
Alosetron—Cough—Doxorubicin—thyroid cancer	0.000738	0.00121	CcSEcCtD
Alosetron—Hypertension—Doxorubicin—thyroid cancer	0.000731	0.0012	CcSEcCtD
Alosetron—Skin disorder—Epirubicin—thyroid cancer	0.000725	0.00119	CcSEcCtD
Alosetron—Hyperhidrosis—Epirubicin—thyroid cancer	0.000722	0.00119	CcSEcCtD
Alosetron—Myalgia—Doxorubicin—thyroid cancer	0.00072	0.00118	CcSEcCtD
Alosetron—Anxiety—Doxorubicin—thyroid cancer	0.000718	0.00118	CcSEcCtD
Alosetron—Discomfort—Doxorubicin—thyroid cancer	0.000712	0.00117	CcSEcCtD
Alosetron—Dry mouth—Doxorubicin—thyroid cancer	0.000705	0.00116	CcSEcCtD
Alosetron—Confusional state—Doxorubicin—thyroid cancer	0.000696	0.00114	CcSEcCtD
Alosetron—Infection—Doxorubicin—thyroid cancer	0.000686	0.00113	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00068	0.00112	CcSEcCtD
Alosetron—Skin disorder—Doxorubicin—thyroid cancer	0.000671	0.0011	CcSEcCtD
Alosetron—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000668	0.0011	CcSEcCtD
Alosetron—Fatigue—Epirubicin—thyroid cancer	0.000644	0.00106	CcSEcCtD
Alosetron—Pain—Epirubicin—thyroid cancer	0.000638	0.00105	CcSEcCtD
Alosetron—Constipation—Epirubicin—thyroid cancer	0.000638	0.00105	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000629	0.00103	CcSEcCtD
Alosetron—Feeling abnormal—Epirubicin—thyroid cancer	0.000615	0.00101	CcSEcCtD
Alosetron—Fatigue—Doxorubicin—thyroid cancer	0.000595	0.000979	CcSEcCtD
Alosetron—Urticaria—Epirubicin—thyroid cancer	0.000593	0.000975	CcSEcCtD
Alosetron—Constipation—Doxorubicin—thyroid cancer	0.000591	0.000971	CcSEcCtD
Alosetron—Pain—Doxorubicin—thyroid cancer	0.000591	0.000971	CcSEcCtD
Alosetron—Feeling abnormal—Doxorubicin—thyroid cancer	0.000569	0.000936	CcSEcCtD
Alosetron—Hypersensitivity—Epirubicin—thyroid cancer	0.00055	0.000904	CcSEcCtD
Alosetron—Urticaria—Doxorubicin—thyroid cancer	0.000549	0.000902	CcSEcCtD
Alosetron—Asthenia—Epirubicin—thyroid cancer	0.000536	0.00088	CcSEcCtD
Alosetron—Hypersensitivity—Doxorubicin—thyroid cancer	0.000509	0.000837	CcSEcCtD
Alosetron—Asthenia—Doxorubicin—thyroid cancer	0.000496	0.000815	CcSEcCtD
Alosetron—Vomiting—Epirubicin—thyroid cancer	0.000475	0.00078	CcSEcCtD
Alosetron—Rash—Epirubicin—thyroid cancer	0.000471	0.000774	CcSEcCtD
Alosetron—Dermatitis—Epirubicin—thyroid cancer	0.00047	0.000773	CcSEcCtD
Alosetron—Headache—Epirubicin—thyroid cancer	0.000468	0.000769	CcSEcCtD
Alosetron—Nausea—Epirubicin—thyroid cancer	0.000443	0.000729	CcSEcCtD
Alosetron—Vomiting—Doxorubicin—thyroid cancer	0.000439	0.000722	CcSEcCtD
Alosetron—Rash—Doxorubicin—thyroid cancer	0.000435	0.000716	CcSEcCtD
Alosetron—Dermatitis—Doxorubicin—thyroid cancer	0.000435	0.000715	CcSEcCtD
Alosetron—Headache—Doxorubicin—thyroid cancer	0.000433	0.000711	CcSEcCtD
Alosetron—Nausea—Doxorubicin—thyroid cancer	0.00041	0.000674	CcSEcCtD
